A Study of LY2189265 Compared to Sitagliptin in Participants With Type 2 Diabetes Mellitus on Metformin

NCT00734474 · Completed

Last updated 2026-05-28

This clinical trial compares the effects of the medication LY2189265 to sitagliptin in adults with type 2 diabetes who are already taking metformin.

Status Completed The study has finished.

Phase Phase2, Phase3

Type Interventional (clinical trial)

Design Randomized, quadruple-blind treatment study

Participants 1,202 people

Who can join Ages 18–75 · all sexes

Timeline Started 2008-08 · est. completion 2012-07

Where 99 sites · Canada, France, Germany, India, Mexico, Poland, Puerto Rico, Romania, Russia, South Korea, Spain, Taiwan, United States

What this study is testing ClinicalTrials.gov NCT00734474 ↗

Description as written by the study sponsor.

This is an adaptive dose finding study and a Phase 3 efficacy study to evaluate the effects of once weekly injection of LY2189265 compared to Sitagliptin on glucose by measuring glycosylated hemoglobin (HbA1c) change from baseline after 52 weeks in participants with type 2 diabetes mellitus on Metformin.

Treatments tested

LY2189265 also known as Dulaglutide, Trulicity Drug
Sitagliptin Drug
Placebo solution Drug
Placebo tablet Drug
Metformin Drug

Main thing measured	Glycosylated Hemoglobin (HbA1c) Change From Baseline
Sponsor	Eli Lilly and Company
Conditions studied	Diabetes Mellitus, Type 2
GLP-1 drugs	—

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT00734474 ↗